vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Xometry, Inc. (XMTR). Click either name above to swap in a different company.
Xometry, Inc. is the larger business by last-quarter revenue ($192.4M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 29.5%). Over the past eight quarters, Xometry, Inc.'s revenue compounded faster (25.2% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Xometry is an online marketplace for sourcing on-demand manufactured parts for prototyping and large-scale production.
ESPR vs XMTR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $192.4M |
| Net Profit | — | $-8.6M |
| Gross Margin | — | 39.1% |
| Operating Margin | 50.6% | -4.6% |
| Net Margin | — | -4.5% |
| Revenue YoY | 143.7% | 29.5% |
| Net Profit YoY | — | 12.7% |
| EPS (diluted) | $0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $192.4M | ||
| Q3 25 | $87.3M | $180.7M | ||
| Q2 25 | $82.4M | $162.5M | ||
| Q1 25 | $65.0M | $151.0M | ||
| Q4 24 | $69.1M | $148.5M | ||
| Q3 24 | $51.6M | $141.7M | ||
| Q2 24 | $73.8M | $132.6M | ||
| Q1 24 | $137.7M | $122.7M |
| Q4 25 | — | $-8.6M | ||
| Q3 25 | $-31.3M | $-11.6M | ||
| Q2 25 | $-12.7M | $-26.4M | ||
| Q1 25 | $-40.5M | $-15.1M | ||
| Q4 24 | — | $-9.9M | ||
| Q3 24 | $-29.5M | $-10.2M | ||
| Q2 24 | $-61.9M | $-13.7M | ||
| Q1 24 | $61.0M | $-16.6M |
| Q4 25 | — | 39.1% | ||
| Q3 25 | — | 39.9% | ||
| Q2 25 | — | 40.1% | ||
| Q1 25 | — | 37.3% | ||
| Q4 24 | — | 39.7% | ||
| Q3 24 | — | 39.4% | ||
| Q2 24 | — | 39.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | 50.6% | -4.6% | ||
| Q3 25 | -11.4% | -6.1% | ||
| Q2 25 | 8.6% | -6.3% | ||
| Q1 25 | -34.0% | -10.2% | ||
| Q4 24 | -6.4% | -7.8% | ||
| Q3 24 | -31.0% | -8.1% | ||
| Q2 24 | 3.5% | -11.5% | ||
| Q1 24 | 52.5% | -14.6% |
| Q4 25 | — | -4.5% | ||
| Q3 25 | -35.9% | -6.4% | ||
| Q2 25 | -15.4% | -16.3% | ||
| Q1 25 | -62.2% | -10.0% | ||
| Q4 24 | — | -6.7% | ||
| Q3 24 | -57.2% | -7.2% | ||
| Q2 24 | -83.9% | -10.3% | ||
| Q1 24 | 44.3% | -13.5% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $0.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $219.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $275.6M |
| Total Assets | $465.9M | $703.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $219.1M | ||
| Q3 25 | $92.4M | $224.5M | ||
| Q2 25 | $86.1M | $225.8M | ||
| Q1 25 | $114.6M | $231.4M | ||
| Q4 24 | $144.8M | $239.8M | ||
| Q3 24 | $144.7M | $234.0M | ||
| Q2 24 | $189.3M | $240.9M | ||
| Q1 24 | $226.6M | $253.8M |
| Q4 25 | $-302.0M | $275.6M | ||
| Q3 25 | $-451.4M | $272.0M | ||
| Q2 25 | $-433.5M | $270.4M | ||
| Q1 25 | $-426.2M | $309.9M | ||
| Q4 24 | $-388.7M | $314.5M | ||
| Q3 24 | $-370.2M | $315.2M | ||
| Q2 24 | $-344.2M | $315.8M | ||
| Q1 24 | $-294.3M | $320.4M |
| Q4 25 | $465.9M | $703.7M | ||
| Q3 25 | $364.0M | $698.9M | ||
| Q2 25 | $347.1M | $687.0M | ||
| Q1 25 | $324.0M | $690.1M | ||
| Q4 24 | $343.8M | $680.1M | ||
| Q3 24 | $314.1M | $678.2M | ||
| Q2 24 | $352.3M | $678.6M | ||
| Q1 24 | $373.1M | $692.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $4.4M |
| Free Cash FlowOCF − Capex | — | $-5.9M |
| FCF MarginFCF / Revenue | — | -3.0% |
| Capex IntensityCapex / Revenue | 0.0% | 5.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-24.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $4.4M | ||
| Q3 25 | $-4.3M | $5.8M | ||
| Q2 25 | $-31.4M | $-427.0K | ||
| Q1 25 | $-22.6M | $-3.7M | ||
| Q4 24 | $-35.0M | $9.1M | ||
| Q3 24 | $-35.3M | $-3.6M | ||
| Q2 24 | $-7.2M | $-9.1M | ||
| Q1 24 | $53.8M | $-11.7M |
| Q4 25 | — | $-5.9M | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-9.2M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $-35.5M | $-8.4M | ||
| Q2 24 | $-7.3M | $-13.5M | ||
| Q1 24 | $53.8M | $-16.1M |
| Q4 25 | — | -3.0% | ||
| Q3 25 | — | -0.9% | ||
| Q2 25 | — | -4.5% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | -68.7% | -6.0% | ||
| Q2 24 | -9.9% | -10.2% | ||
| Q1 24 | 39.0% | -13.1% |
| Q4 25 | 0.0% | 5.3% | ||
| Q3 25 | 0.0% | 4.1% | ||
| Q2 25 | 0.0% | 4.3% | ||
| Q1 25 | 0.0% | 3.6% | ||
| Q4 24 | 0.0% | 3.1% | ||
| Q3 24 | 0.3% | 3.4% | ||
| Q2 24 | 0.1% | 3.3% | ||
| Q1 24 | 0.1% | 3.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
